Radiotherapy after reconstruction: local control, capsular contracture, and the 1–3 node grey zone

Selena — radiation oncologist; director of training

Australian and New Zealand radiation oncology training. Otter’s introduction is badly garbled: “master’s degree in budget from Lindsay University,” “fellowship in Sarkova in Sheffield in 1911,” “Selena communist Genesis King in 2007,” and “training wishes in race, brain, and skin cancers.” Likely reading: a Sheffield fellowship around 2011 (FRCR-era, not 1911), commencing locally around 2007, with clinical interests in breast, brain, and skin. This write-up does not invent a surname. She is the radiation oncology voice after Marie’s reconstruction talk — this session is radiotherapy after reconstruction, not implant versus flap types.

Marie (same evening, not this recording)

Already covered reconstruction types. Selena does not repeat that. Companion medical-oncology write-up from the same Gold Coast CPD day: breast-treatment.drkotha.com. Same-day imaging: breast-imaging.drkotha.com.

Who was speaking — and what Otter mangled

Otter’s first two minutes are almost unusable. A host tries to introduce Selena: a master’s Otter heard as “budget from Lindsay University,” a “fellowship in Sarkova in Sheffield in 1911,” commencing around 2007, training interests Otter heard as “race, brain, and skin cancers,” and “director of training with an Australian New Zealand radiologist, radiation coaching ministers.”

Selena then takes the microphone: “my name is Selena,” and she is a radiation oncologist. The rest of the talk is coherent enough to use. This write-up treats her as Selena, radiation oncologist, director of training in Australian and New Zealand radiation oncology, with breast, brain, and skin among her interests. The Sheffield line is most likely an FRCR-era fellowship around 2011, not 1911. We do not guess her surname. We do not promote her to a title she did not claim.

She starts with a case, then “the rest of radio.” Marie has already done reconstruction types. This is radiotherapy after reconstruction.

The 47-year-old: seven lesions, nine foci, a positive margin

A 47-year-old woman presented with a palpable lump. Imaging showed a density and two masses. Biopsy confirmed invasive cancer. MRI then showed seven lesions.

She went on to bilateral nipple-sparing mastectomy (Otter: “nipple squaring mastectomy”), sentinel node biopsy (Otter: “central neurobioxy”), and implant reconstruction (Otter: “directed and cutting reconstruction” — most likely direct-to-implant; we do not invent a technique Otter did not clearly name).

Histology was more disease than the MRI count: nine foci of invasive cancer, 6 millimetres to 12 millimetres, spread over about a 95 × 17 millimetre area. Grade 2. Associated high-grade DCIS (Otter: “high grade ductal custodian respiratory,” later “ductal carcinoma syrupy”).

The surgical margin was involved — invasive cancer and DCIS (Otter: “involved mild advancing cancer and ductal carcinoma syrupy”). Nodes were negative. Receptor status: ER positive, HER2 negative (Otter: “formal precepts, so positive and her affair was negative”).

Otherwise well. Discussed in a multidisciplinary meeting. Plan: chemotherapy, then radiotherapy, then ovarian suppression and hormone therapy.

Five weeks, a boost, and bolus on the implant

Radiotherapy was five weeks to the reconstructed breast, then a higher dose — a boost — to the positive-margin area (Otter: “a higher dose for foods to the area of so-called positive margin”). Total about six and a half weeks.

She showed a plan: the whole implant in the field, an inner circle for the boost volume, and a layer of tissue-equivalent material on the skin. Otter heard “bonus.” That is bolus — a tissue-equivalent sheet that pulls dose up to the skin, which you otherwise under-dose because of the build-up region. In a reconstructed chest wall, that is a deliberate choice when you need skin coverage.

She did not give gray, fractionation, or a named technique in the recording. This page does not invent them.

Week 5 dermatitis, month 1 settled, month 6 contracture

Left photo, about week 5: radiotherapy dermatitis, worse toward the axilla (Otter: “upper development towards the axilla”), plus discoloration (Otter: “disclamation”).

Right photo, about one month after finishing: much of the acute reaction has settled. “Her breast and her implant looks sort of relatively good.”

Next photo, six months later: pain and contracture of the right chest wall, reduction in size, and “a fine blood vessel developing” — telangiectasia. Discomfort enough that she went on to fat grafting and implant replacement (Otter: “more of the implant grafting and replacement”).

Why radiotherapy is the “bad cop”

Mechanism, as she put it: radiotherapy causes cell death and cell damage. That activates fibroblasts. Fibrosis follows. Vessels in the skin and the tissue underneath are affected. Wound healing is slower. Superficial skin can be lost; ulceration can follow. Paired with poorer blood flow, you get more healing trouble and more fibrosis.

Downstream of that, on a reconstructed chest:

• Capsular contracture around the implant.
• Implant malposition (Otter: “no position of the implant”) and poor cosmetic outcome (Otter: “poor cognitive outcome”).
• Wound breakdown, infection, necrosis.
• Ultimately reconstruction failure and implant loss.
• Autologous reconstruction is not immune: flap contracture (Otter: “flat contracture”) can happen too.

Early skin reaction (the week-5 dermatitis) and late fibrosis / contracture / telangiectasia are the same treatment on two clocks. The late clock is the one that wrecks a reconstruction.

Why reconstruct at all

Marie has already covered types. Selena only restates the why: improve body image, psychological wellbeing, and quality of life; clothes fitting better; avoiding an external prosthesis (Otter: “resp prostheses”).

That is the other side of the ledger she comes back to at the end. Radiotherapy can damage the very reconstruction that was meant to protect those things. The question is not “reconstruction or radiotherapy.” It is how you hold both.

Why we still give radiotherapy

Aim: reduce chest-wall recurrence and nodal recurrence. Nodes: axilla, internal mammary (Otter: “fossil or change the breast also drains too”), and the supraclavicular chain. She showed PET and CT examples. Local control is not only a local story: reducing locoregional recurrence improves survival.

The graphs she showed were an old meta-analysis of post-mastectomy radiotherapy after axillary dissection.

She is explicit that those graphs are old, and that chemotherapy has “come a long way.” That caveat matters most in the 1–3 node group. Do not treat 20% → 4% as the risk for a 2026 woman who has had modern chemo and a sentinel node rather than a dissection.

Hard indications versus the 1–3 node grey zone

“Basically patients who have big tumours and patients who have many lymph nodes involved.”

Hard indications, as she listed them

• Four or more lymph nodes involved.
• Tumour more than 5 centimetres.
• Skin involvement or muscle involvement.
• Involved surgical margins when further surgery is not possible — the case she started with.

The intermediate / grey zone

Smaller tumours, under 5 centimetres, with one to three nodes — or a slightly larger tumour — plus extra risk:

• High grade
• Lymphovascular invasion (Otter: “lymphascular invasion”)
• Multiple foci / multifocal disease
• Young age
• Hormone-receptor negative

In that band, discuss the pros and cons. It is “very much a balancing act.” The 1–3 node group is controversial because the meta-analysis is old and systemic therapy has moved.

Everything belongs in MDT — sometimes before the knife

“Treatment of breast cancer is getting more and more complicated.” Timing of chemotherapy, timing of radiotherapy, whether they need radiotherapy at all — all of it is changing. Every breast cancer case is discussed in a multidisciplinary setting. Often after surgery. Sometimes before surgery: is there a role for chemotherapy first (Otter: neoadjuvant came out as “neatrian” later in the talk)? Might she need radiotherapy? That last question changes reconstruction choices.

For GPs: if a woman is heading toward mastectomy plus reconstruction, the useful question is not “did the surgeon offer an implant?” It is “has MDT already asked whether the chest wall is likely to need radiotherapy?”

Complications: about 24% without RT, about 33% with it

Reconstruction itself has complications. Radiotherapy increases them. The table she showed, about two years after reconstruction (Otter: “two years post-option of flee”):

A definite increase. Not a doubling. Any reconstruction can go wrong; radiotherapy loads the dice.

Satisfaction studies, implant and autologous (Otter: “autonomous reconstruction”): breast satisfaction, outcome, psychological wellbeing, physical wellbeing — overall scoring relatively high. Women who had radiotherapy score a bit lower. “Still not too bad.”

How to move forward: dose, volumes, de-escalation, salvage

Side effects are related to dose. If you do not need a higher dose, do not give a boost — less fibrosis, less contracture. Then: de-escalate and find who may not need radiotherapy at all. Then: volumes — whole breast (or chest wall) plus nodes, versus omitting the nodes.

An unpublished trial she mentioned

A relatively recent, unpublished trial: after neoadjuvant chemotherapy (Otter: “neatrian chemotherapy”), women with a pathological complete response were randomised to regional nodal radiotherapy or not (Otter: “regional motor,” “superficial vals exit” — read as regional nodes including the supraclavicular fossa and axilla). In that complete-response group, omitting nodal RT made no difference (Otter: “no actual difference in both transplants” — she is talking endpoints, not transplants).

Select group: they had high-risk features going in, then a complete response. That may be a group who can omit. Unpublished, as she said. Not a protocol.

When the reconstruction is already damaged

Salvage she listed: capsulectomy (Otter: “captured ectomy”), fat grafting, implant exchange. That is what the 47-year-old needed at six months.

Take-home messages for clinic

1. Selena is a radiation oncologist and director of training. Otter mangled her surname and credentials (“Sarkova in Sheffield in 1911”). Do not invent a name. This talk is RT after reconstruction; Marie already did reconstruction types. Companions: imaging and medical oncology.
2. The teaching case: 47, palpable lump, two masses, seven MRI lesions, bilateral nipple-sparing mastectomy, sentinel node, implant reconstruction. Nine foci 6–12 mm over ~95 × 17 mm, grade 2, high-grade DCIS, involved margin (invasive + DCIS), nodes negative, ER positive / HER2 negative. No further surgery possible. MDT: chemo → RT → ovarian suppression + hormone therapy.
3. RT: five weeks to the reconstructed breast, then a boost to the positive-margin area, bolus (Otter: bonus) to bring dose to skin. Total ~6.5 weeks. Week 5: dermatitis toward the axilla. One month: largely settled. Six months: pain, contracture, smaller right chest wall, telangiectasia, then fat grafting and implant replacement. Relatively early capsular contracture. “Radiotherapy is the bad cop.”
4. Mechanism: cell death and damage → fibroblast activation → fibrosis; vessels in skin and subcut; wound healing; superficial skin loss; implant malposition, poor cosmetic outcome, infection, necrosis, reconstruction failure. Autologous flaps can contract too.
5. We reconstruct for body image, psychological wellbeing, quality of life, clothes, and to avoid an external prosthesis. We still irradiate to cut chest-wall and nodal recurrence (axilla, internal mammary, supraclavicular). Local control improves survival.
6. Old meta-analysis after mastectomy and axillary dissection: 1–3 nodes, 10-year locoregional recurrence ~20% → 4%, 20-year OS ~8% absolute. Similar direction if ≥4 nodes. Those graphs are old. Chemo has moved. Do not quote them as 2026 individual risk.
7. Hard: ≥4 nodes; tumour >5 cm; skin or muscle involvement; involved margins when further surgery is not possible. Grey zone: <5 cm and 1–3 nodes, or a larger tumour, plus high grade, LVI, multifocal, young, hormone-receptor negative — discuss. A more recent intermediate-risk trial did not show DFS/OS gain, but everyone had axillary dissection; we now aim for sentinel node and to avoid dissection.
8. Every breast cancer in MDT. Sometimes before surgery: neoadjuvant? Will she need RT? That changes reconstruction.
9. Complications at ~2 years: reconstruction alone ~23–24%; with RT ~33%. Satisfaction still relatively high for implant and autologous; RT a bit lower, “still not too bad.”
10. Move forward: skip the boost if you do not need it; de-escalate and find who can omit RT; think about nodal volumes. Unpublished neoadjuvant pCR trial: regional nodal RT versus not — no difference if pCR. Salvage: capsulectomy, fat grafting, implant exchange. It is all a balance.

Dr Kotha · Gold Coast · breast-radiotherapy.drkotha.com